WO2018052153A1 - 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도 - Google Patents
티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도 Download PDFInfo
- Publication number
- WO2018052153A1 WO2018052153A1 PCT/KR2016/010381 KR2016010381W WO2018052153A1 WO 2018052153 A1 WO2018052153 A1 WO 2018052153A1 KR 2016010381 W KR2016010381 W KR 2016010381W WO 2018052153 A1 WO2018052153 A1 WO 2018052153A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
Definitions
- the present invention relates to a monoclonal antibody that specifically binds to thioredoxin 1 and its use, and more particularly to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to thioredoxin 1, the antibody or its Nucleic acid molecules encoding heavy and / or light chains of antigen-binding fragments, recombinant vectors comprising the nucleic acid molecules, host cells, methods for producing the antibody or antigen-binding fragments thereof, kits for diagnosing breast cancer, and providing information for diagnosing breast cancer It is about a method.
- Thioredoxin is a small redox protein on the order of 12 kDa that undergoes NADPH dependent reduction by thioredoxin reductase, and includes mammalian thioredoxin 1 (Trx1) and thioredoxin 2 (Trx2).
- Thioredoxin acts as a growth factor, removes hydrogen peroxide that is toxic in cells, binds DNA to important elements involved in ribonucleotide reductase and transcriptional activity in bacteria, and is involved in transcription in eukaryotic cells. It affects the activity of the factor, nuclear transcription factor kB (NF-kB).
- NF-kB nuclear transcription factor kB
- thioredoxin plays an important role in regulating cancer cell growth by affecting apoptosis and tumors, and by breaking the disulfide bonds of other oxidized proteins, it helps to have a reduced activity.
- Thioredoxin 1 and 2 enzymes have an effect on cell death by removing nitric oxide of cysteine amino acids in mammalian cells and of potential importance in many diseases, including inflammatory diseases, heart attacks, and cancer.
- immunohistochemical analysis using anti-thioredoxin antibodies shows the expression of thioredoxin in human cancer tissues including liver, colon, pancreas and cervix, which expression is likely to lead to thioredoxin in tumorigenesis. Point to.
- thioredoxin 1 was expressed in low breast tissue but very high in breast cancer tissue. Oredoxin 1 proved to be useful as a marker for diagnosing breast cancer (Korean Patent No. 10-1058230).
- Another object of the present invention is to provide a nucleic acid molecule encoding the heavy and / or light chain of the monoclonal antibody or antigen-binding fragment thereof.
- Still another object of the present invention is to provide a recombinant vector comprising the nucleic acid molecule.
- Another object of the present invention to provide a host cell comprising the recombinant vector.
- Still another object of the present invention is to provide a method for producing a monoclonal antibody or antigen-binding fragment thereof that specifically binds thioredoxin 1, comprising culturing the host cell.
- Another object of the present invention is to provide a breast cancer diagnostic kit comprising the aforementioned monoclonal antibody or antigen-binding fragment thereof.
- the present invention provides a light chain variable region comprising a light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 1, a light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 2 and a light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 3, And a heavy chain variable region comprising a heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 5, and a heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 6 It provides a monoclonal antibody or antigen-binding fragment thereof that binds to.
- the antibody may comprise a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 14.
- the antibody may comprise a light chain consisting of the amino acid sequence of SEQ ID NO: 17 and a heavy chain consisting of the amino acid sequence of SEQ ID NO: 18.
- the present invention also provides a light chain variable region comprising a light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 7, a light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 8, and a light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 9, and an amino acid of SEQ ID NO: 10
- Monoclonal antibody that specifically binds to thioredoxin 1, comprising a heavy chain CDR1 consisting of a heavy chain CDR1 consisting of a sequence, a heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 12 Or antigen binding fragments thereof.
- the antibody may comprise a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 15 and a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 16.
- the antibody may comprise a light chain consisting of the amino acid sequence of SEQ ID NO: 19 and a heavy chain consisting of the amino acid sequence of SEQ ID NO: 20.
- the antibody may comprise an IgG1 heavy chain and kappa ( ⁇ ) light chain.
- the antigen binding fragment may be Fab, F (ab '), F (ab') 2 , Fv or a single chain antibody molecule.
- the antibody may be a chimeric antibody, a humanized antibody or a human antibody.
- the present invention also provides nucleic acid molecules encoding the heavy and / or light chains of the aforementioned antibodies or antigen-binding fragments thereof.
- the nucleic acid molecule encoding the light chain may be composed of the nucleotide sequence of SEQ ID NO: 21 or the nucleotide sequence of SEQ ID NO: 23.
- the nucleic acid molecule encoding the heavy chain may be composed of the nucleotide sequence of SEQ ID NO: 22 or the nucleotide sequence of SEQ ID NO: 24.
- the present invention also provides a recombinant vector comprising both a nucleic acid molecule encoding the heavy chain, a nucleic acid molecule encoding the light chain or a nucleic acid molecule encoding the heavy and light chain.
- the present invention also provides a method for producing a monoclonal antibody or antigen-binding fragment thereof that specifically binds thioredoxin 1, comprising culturing the host cell and the host cell comprising the recombinant vector.
- the present invention also provides a breast cancer diagnostic kit comprising the above-described antibody or antigen-binding fragment thereof.
- the kit may be an Enzyme Linked Immunosorbent Assay (ELISA) kit.
- ELISA Enzyme Linked Immunosorbent Assay
- the ELISA may be any one selected from the group consisting of direct ELISA, indirect ELISA, direct sandwich ELISA and indirect sandwich ELISA.
- the invention also comprises the steps of (a) contacting the monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 4 with a biological sample isolated from a subject suspected of breast cancer; (b) measuring the expression level of thioredoxin 1 protein bound to a monoclonal antibody or antigen-binding fragment thereof in the biological sample through antigen-antibody complex formation; And (c) comparing the expression level of the thioredoxin 1 protein measured in step (b) with the control group and determining the breast cancer patient if the expression level of the protein is higher than that of the control group. It provides a method for providing information necessary for diagnosing breast cancer.
- the present invention further comprises the steps of: (a) coating a solid support with the monoclonal antibody or antigen-binding fragment thereof of claim 2, 4 or 6; (b) applying a biological sample isolated from the individual suspected of breast cancer to the coated solid support; (c) removing the unbound sample; (d) applying the monoclonal antibody or antigen-binding fragment thereof of claim 1, 3 or 5 to a solid support; (e) removing unbound monoclonal antibodies or antigen binding fragments thereof; (f) measuring the expression level of thioredoxin 1 protein; And (g) comparing the expression level of the thioredoxin 1 protein measured in step (f) with the control group, and determining the breast cancer patient if the expression level of the protein is higher than that of the control group. It provides a method for providing information necessary for diagnosing breast cancer.
- the expression level of the thioredoxin 1 protein is Western blot, ELISA, sandwich ELISA, radioimmunoassay, radioimmunoproliferation method, oukteroni immune diffusion method, immunoprecipitation assay, complement fixation assay It can be measured by any one method selected from the group consisting of any one or more of the method, immunochromatography, FACS and protein chip method.
- the isolated biological sample may be any one or more selected from the group consisting of whole blood, serum, plasma, breast tissue and breast cells.
- antigen refers to a molecule or portion of a molecule that can be bound by an antibody and can also be used in an animal to produce an antibody that can also bind to an epitope of an antigen.
- the antigen may have one or more epitopes.
- antibody refers to immunity capable of recognizing and binding to specific targets or antigens, such as carbohydrates, polynucleotides, lipids, polypeptides, etc., via one or more antigen recognition sites, located in the variable region of an immunoglobulin molecule. Globulin molecule.
- antibody refers to monoclonal antibodies; Polyclonal antibodies; “Antigen binding fragments” of antibodies that possess the ability to specifically bind to a particular antigen (eg, Trx1), such as Fab, Fab ', F (ab') 2 , Fd, Fv, Fc, and the like; Isolated complementarity determining regions (CDRs); Bispecific antibodies; Heterozygous antibodies, mutants thereof; Fusion proteins with antibodies, or antigen-binding fragments thereof (eg, domain antibodies); Single chain (ScFv) and single domain antibodies (eg, shark and camelid antibodies); Maxibody, minibody, intrabody, diabody, triabody, tetrabody, v-NAR and bis-scFv; Humanized antibodies; Chimeric antibodies; And all other modified conformations of immunoglobulin molecules including antigen recognition sites of the required specificity (including, but not limited to, glycosylation variants of antibodies, amino acid sequence variants of antibodies and covalent
- Antibodies or polypeptides that "specifically bind" with a particular target or antigen are terms well understood in the art, and methods for determining such specific binding are also well known in the art. It is. Certain molecules are shown to exhibit "specific binding” when they react or associate with a particular cell or substance more frequently, more quickly, with greater persistence and / or with greater affinity than with another cell or substance. Is considered. Certain antibodies “specifically bind” to specific targets or antigens when they bind with greater affinity, binding activity, faster and / or greater persistence than binding other substances.
- binding affinity is intended to refer to the equilibrium dissociation constant of a particular antigen-antibody interaction.
- K D is the ratio of the dissociation rate (also called “breakaway rate” or “k d ”) to binding rate, or “operating rate” or "k a (association rate constant)”. Therefore, K D is k d / k a , which is expressed as molar concentration (M). It is concluded that the smaller the K D , the stronger the binding affinity. Therefore, 1 ⁇ M of K D indicates weak binding affinity compared to 1 nM of K D.
- K D values for antibodies can be determined using methods well established in the art. One method of determining the K D of an antibody is to use surface plasmon resonance, typically using a biosensor system, such as a Biacore® system.
- vector includes nucleic acid molecules capable of carrying other linked nucleic acids.
- plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be bound.
- viral vector Another form of the vector is a viral vector, wherein additional DNA segments can be bound to the viral genome.
- Some vectors can autonomously replicate in the host cell into which they are introduced (eg, bacterial vectors and episomal mammalian vectors with bacterial origin replication).
- Other vectors eg, non-episomal mammalian vectors
- certain vectors may direct the expression of genes to which they are operatively linked.
- vectors are referred to herein as "recombinant expression vectors (or simply," expression vectors ").
- expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Vector can be used interchangeably because the plasmid is the most commonly used form of vector, however, the present invention can be used interchangeably with other forms of expression vectors, such as viral vectors (e.g., lack of replication). Retroviruses, adenoviruses and adeno-associated viruses).
- host cell is used to mean a cell that can be transformed or transformed by a nucleic acid sequence and then express the gene of interest.
- the term includes the progeny of the parent cell, as long as the selected gene is present, whether the progeny is morphologically or genetically identical to the original parent.
- the monoclonal antibody of the present invention has excellent binding affinity for thioredoxin 1, which binds specifically to thioredoxin 1, and also has high sensitivity and specificity, and thus may be useful for screening breast cancer patients. Furthermore, detection of thioredoxin 1 using a monoclonal antibody that specifically binds to thioredoxin 1 of the present invention, rather than detection of another conventional breast cancer diagnostic biomarker CA15-3, has sensitivity and specificity. Its superiority can significantly increase the accuracy and reliability of breast cancer diagnosis.
- FIG. 1 shows a cleavage map of a recombinant vector expressing thioredoxin 1 antigen and isotyping results of the antibody obtained in Example 1.
- Figure 2 shows the light chain (a) and heavy chain (b) amino acid sequence of the 9G7 (AB1) antibody obtained in Example 1.
- Figure 3 shows the light chain (a) and heavy chain (b) amino acid sequence of the 2B4 (AB2) antibody obtained in Example 1.
- FIG. 4 shows a cleavage map of recombinant vectors expressing light chain (a) and heavy chain (b) of antibody B264 with good affinity.
- Fig. 5 shows a cleavage map of recombinant vectors expressing light chain (a) and heavy chain (b) of antibody B266 with good affinity.
- Figure 6 confirms the reduced (+) and non-reduced (-) state of the antibody using SDS-PAGE, (a) shows antibody B264, (b) shows antibody B266.
- Figure 7 confirms the reduced (+) and non-reduced (-) state of antibody B266-1 using SDS-PAGE, the antibody B266-1 is a change in the Fc portion of antibody B266 human IgG1.
- Figure 9 shows the results of calculating the sensitivity and specificity by ROC analysis of the results by ELISA using antibodies B266-1 and B264.
- thioredoxin 1 is low in normal breast tissue but very high in breast cancer tissue, and that thioredoxin 1 is useful as a marker for diagnosing breast cancer.
- the monoclonal antibody of the present invention has excellent binding affinity for thioredoxin 1, which binds specifically to thioredoxin 1, and also has high sensitivity and specificity, and thus may be useful for screening breast cancer patients. Furthermore, detection of thioredoxin 1 using a monoclonal antibody that specifically binds to thioredoxin 1 of the present invention, rather than detection of another conventional breast cancer diagnostic biomarker CA15-3, has sensitivity and specificity. Its superiority can significantly increase the accuracy and reliability of breast cancer diagnosis.
- the present invention provides a monoclonal antibody or antigen-binding fragment thereof that binds to human thioredoxin-1 (Trx1).
- Monoclonal antibodies of the present invention can be prepared using a wide variety of techniques known in the art, such as hybridomas, recombinant and phage display techniques, or methods using combinations thereof.
- monoclonal antibodies can be prepared using hybridoma techniques, such as those known in the art.
- the term “monoclonal antibody” herein does not limit only antibodies produced through hybridoma technology.
- the term “monoclonal antibody” refers to an antibody derived from a monoclonal such as any eukaryotic, prokaryotic or phage clone, but not a method of production thereof.
- mice can be immunized with a target antigen or cells expressing such antigen.
- an immune response is detected, for example, when an antibody specific for an antigen is detected in mouse serum, the mouse spleen is recovered to separate splenocytes.
- the splenocytes are then fused with any suitable myeloma cells, such as P3U1, P3X63-Ag8, P3X63-Ag8-U1, P3NS1-Ag4, SP2 / 0-Ag14, P3X63-Ag8-653, etc., using known techniques. .
- Hybridomas are selected and cloned by limiting dilution.
- the hybridoma clones are then assessed for their ability to secrete antibodies capable of binding antigen by methods known in the art.
- ascites containing high levels of antibodies can be made by inoculating a mouse abdominal cavity with a positive hybridoma clone.
- the recombinant vector having the cleavage map of Figure 1 (a) was transfected into E. coli to prepare a Trx1 antigen. Subsequently, the spleens of mice immunized with the antigen were isolated and fused with myeloma cells (sp2 / 0) to identify cells producing antibodies that react with Trx1 by ELISA.
- Preferred monoclonal antibodies or antigen-binding fragments thereof of the invention may comprise the following (a) or (b), which may be referred to herein as B264 and B266-1, respectively:
- a light chain variable region comprising a light chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 1, a light chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 2, and a light chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 3, and an amino acid sequence of SEQ ID NO: 4
- a heavy chain variable region comprising a heavy chain CDR1 consisting of a heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 5 and a heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 6; or
- a light chain variable region comprising a light chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 7, a light chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 8, and a light chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 9, and an amino acid sequence of SEQ ID NO: 10
- a heavy chain variable region comprising a heavy chain CDR1 consisting of a heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 11 and a heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 12;
- the term “complementarity determining region” refers to the amino acid sequence of the hypervariable region of an immunoglobulin heavy and light chain.
- the heavy chains (CDRH1, CDRH2 and CDRH3) and light chains (CDRL1, CDRL2 and CDRL3) each contain three CDRs, which provide the major contact residues for the antibody to bind antigen or epitope.
- Preferred monoclonal antibodies or antigen-binding fragments thereof of the invention may comprise the following (c) or (d), which may be referred to herein as B264 and B266-1, respectively:
- Preferred monoclonal antibodies or antigen-binding fragments thereof of the invention may comprise the following (e) or (f), which may be referred to herein as B264 and B266, respectively:
- B264, B265, B266, B267, B268 or B269 Preferred monoclonal antibodies of the invention are referred to as B264, B265, B266, B267, B268 or B269, and most preferably may be B264 or B266-1.
- B266-1 is a monoclonal antibody in which the Fc portion of B266 has been changed to human IgG1.
- Naturally occurring antibody structural units typically include tetramers.
- Each tetramer typically consists of two identical pairs of polypeptide chains, each pair having one full length light chain (typically about 15 kDa) and one full length heavy chain (typically about 50 to 70 kDa) .
- the amino-terminal region of each of the light and heavy chains typically comprises a variable region of about 100 to 110 or more amino acids involved in antigen recognition.
- the carboxy-terminal portion of each chain typically defines constant regions involved in effector function.
- Human light chains are commonly classified as kappa ( ⁇ ) and lambda ( ⁇ ) light chains.
- Heavy chains are typically classified as mu, delta, gamma, alpha or epsilon and define the isotype of the antibody as IgM, IgD, IgG, IgA and IgE, respectively.
- IgG has several subclasses including, but not limited to, IgG1, IgG2, IgG3 and IgG4.
- IgM has, but is not limited to, subclasses including IgM1 and IgM2.
- IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2.
- variable and constant regions are joined by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 10 or more amino acids.
- the variable region of each light / heavy chain pair typically forms an antigen-binding site.
- the heavy chain of the monoclonal antibody of the present invention may be IgG1, IgG2a, IgG2b, IgG3, IgA or IgM isotype
- the light chain may be kappa chain or lambda chain, preferably kappa Light chain and IgG1 heavy chain.
- antigen-binding fragments thereof means fragments having antigen-binding function, and include Fab, F (ab '), F (ab') 2 and Fv or Single chain antibody molecule molecules and the like.
- Fab has one antigen-binding site in a structure having variable regions of the light and heavy chains, constant regions of the light chain, and the first constant region of the heavy chain (CH1).
- F (ab ') differs from Fab in that it has a hinge region comprising one or more cysteine residues at the C-terminus of the heavy chain CH1 domain.
- F (ab ') 2 is produced when the cysteine residues of the hinge region of Fab' form disulfide bonds.
- Fv refers to the minimum antibody fragment having only heavy and variable chain regions.
- Such antibody fragments may be obtained using proteolytic enzymes, for example, restriction digestion of the entire antibody with papain may yield Fab and cleavage with pepsin may yield F (ab ') 2 fragments, preferably Can be produced through genetic recombination techniques.
- Preferred antibodies of the invention can be chimeric antibodies, humanized antibodies or fully human antibodies.
- Chimeric antibodies can be prepared by recombinant means by combining the variable light and heavy chain regions (VL and VH) obtained from one species of antibody producing cells with the constant light and heavy chain regions from another species.
- VL and VH variable light and heavy chain regions
- chimeric antibodies utilize rodent or rabbit variable regions and human constant regions mainly to produce antibodies with human domains. The production of such chimeric antibodies is well known in the art and can be accomplished by standard means.
- Human constant regions of chimeric antibodies of the invention are from IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, IgG7, IgG8, IgG9, IgG10, IgG11, IgG12, IgG13, IgG14, IgG15, IgG16, IgG17, IgG18 or IgG19 constant regions. It is further contemplated that it may be selected.
- Humanized antibodies are engineered to contain even more human-like immunoglobulin domains, which include only the complementarity determining regions of animal derived antibodies. This is accomplished by carefully examining the sequences of the hypervariable loops of the variable regions of monoclonal antibodies and adapting the sequences to the structure of human antibody chains.
- Fully human antibodies are antibody molecules in which the entire sequence of both light and heavy chains, including CDRs, originate from human genes.
- the present invention also provides nucleic acid molecules encoding the heavy and / or light chains of the monoclonal antibodies or antigen-binding fragments thereof of the invention.
- nucleic acid molecule is meant to encompass DNA (gDNA and cDNA) and RNA molecules inclusive, and the nucleotides that are the basic structural units in nucleic acid molecules are natural nucleotides, as well as analogs in which sugar or base sites are modified. (analogue) is also included.
- sequence of nucleic acid molecules encoding heavy and light chain variable regions of the invention can be modified. Such modifications include addition, deletion, or non-conservative or conservative substitutions of nucleotides.
- Nucleic acid molecules of the invention are also construed to include nucleotide sequences that exhibit substantial identity to the nucleotide sequences described above. Such substantial identity is at least 80 when aligning the nucleotide sequence of the present invention with any other sequence to the maximum correspondence, and analyzing the aligned sequence using algorithms commonly used in the art.
- the nucleic acid molecule encoding the light chain of the monoclonal antibody of the present invention may consist of the nucleotide sequence of SEQ ID NO: 21, the nucleic acid molecule encoding the heavy chain consists of the nucleotide sequence of SEQ ID NO: 22 Can be.
- the nucleic acid molecule encoding the heavy chain of the monoclonal antibody of the present invention may be composed of the nucleotide sequence of SEQ ID NO: 23, the nucleic acid molecule encoding the light chain is the nucleotide sequence of SEQ ID NO: 24 It may be made of.
- the present invention also provides a recombinant vector comprising both a nucleic acid molecule encoding a heavy chain and a light chain or a nucleic acid molecule encoding the light chain of the monoclonal antibody.
- the recombinant vector system of the present invention can be constructed through various methods known in the art.
- Vectors of the present invention can typically be constructed as vectors for cloning or vectors for expression.
- the vector of the present invention can be constructed using prokaryotic or eukaryotic cells as hosts.
- the vector of the present invention is an expression vector and the prokaryotic cell is a host
- powerful promoters capable of promoting transcription e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL ⁇ promoter, pR ⁇ promoter
- rac5 promoter amp promoter
- recA promoter recA promoter
- SP6 promoter trp promoter and T7 promoter
- ribosome binding sites for initiation of translation.
- E. coli e.g., HB101, BL21, DH5 ⁇ , etc.
- the promoter and operator sites of the E e.g., HB101, BL21, DH5 ⁇ , etc.
- Bacillus bacteria can be used as host cells, any promoter capable of expressing Bacillus bacteria or a promoter of the toxin protein gene of Bacillus thuringiensis can be used as a regulatory site.
- the recombinant vector of the present invention is a plasmid used in the art (eg, pCL, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX).
- Series, pET series and pUC19, etc. phages (eg, ⁇ gt4 ⁇ ⁇ B, ⁇ -Charon, ⁇ z1 and M13, etc.) or viruses (eg, SV40, etc.).
- promoters derived from the genome of mammalian cells e.g., metallothionine promoter, ⁇ -actin promoter, human heroglobin promoter and human muscle creatine promoter
- a promoter derived from a mammalian virus e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse breast tumor virus (MMTV) promoter, HIV LTR promoter, promoter of Moroni virus Epsteinbar virus (EBV) and Loose sacoma virus (RSV) promoter
- EBV Moroni virus Epsteinbar virus
- RSV Loose sacoma virus
- the recombinant vector of the present invention may be fused with other sequences to facilitate the purification of the antibody expressed therefrom.
- Sequences to be fused include, for example, glutathione S-transferase (Amersham Pharmacia Biotech, USA); Maltose binding protein (NEB, USA); FLAG (IBI, USA); Tag sequences such as 6x His (hexahistidine; Qiagen, USA), Pre-S1, c-Myc; leading sequences such as ompA and pelB .
- the protein expressed by the vector of the present invention is an antibody, the expressed antibody can be easily purified through a protein A column or the like without additional sequences for purification.
- the recombinant vector of the present invention includes antibiotic resistance genes commonly used in the art as a selection marker, for example, ampicillin, gentamycin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin And resistance genes for tetracycline.
- the vector expressing the antibody of the present invention may be a vector system in which the light and heavy chains are simultaneously expressed in one vector, or a system in which the light and heavy chains are expressed in separate vectors, respectively. In the latter case, both vectors are introduced into the host cell via co-transfomation and targeted transformation.
- Simultaneous transformation is a method of introducing each vector DNA encoding a light chain and a heavy chain into a host cell at the same time, and then selecting cells expressing both the light and heavy chains.
- Target transformation involves selecting the cells transformed with the vector containing the light (or heavy) chain and transforming the selected cells expressing the light chain with the vector containing the heavy (or light) chain to express both the light and heavy chains. This is the method of finally selecting the cells.
- the present invention also provides a host cell comprising the recombinant vector of the present invention.
- the host cell is a cell transformed with the recombinant vector of the present invention.
- Host cells capable of continuously cloning and expressing the vector of the present invention in a stable manner are known in the art, and any host cell may be used, for example, Escherichia coli), Bacillus subtilis (Bacillus subtilis) and Bacillus Chuo ringen system (B.
- Bacillus strain Bacillus strain (Bacillus spp such as thuringensis).), Streptomyces (Streptomyces), Pseudomonas (Pseudomonas) (for example, Pseudomonas footage the (Pseudomonas putida)), Proteus Billy's mum (Proteus prokaryotic host cells such as, but not limited to, mirabilis ) or Staphylococcus (eg, Staphylococus carnosus ).
- Suitable eukaryotic host cells of the vector are multicellular fungi and piapas, such as Aspergillus spp. And Neurospora crassa , belonging to Phylum Ascomycota. Pichia pastoris , Saccharomyces cerevisiae ), unicellular fungi including yeasts such as Schizosaccharomyces , other lower eukaryotic cells, cells of higher eukaryotes such as insect-derived cells, and plants or mammals. Cells can be used.
- transfection refers to introducing a desired gene into a host cell using the recombinant vector of the present invention, and is used in the same meaning as “transformation”.
- “transfection” and / or “transformation” into a host cell includes any method of introducing a nucleic acid into an organism, cell, tissue, or organ, and as appropriate to the host cell, as is known in the art, It can be done by selection.
- These methods include electroporation, plasma fusion, calcium phosphate (CaPO 4 ) precipitation, calcium chloride (CaCl 2 ) precipitation, agitation with silicon carbide fibers, agro bacteria mediated transformation, PEG, dextran sulfate, lipo Pectamine and dry / inhibited mediated transformation methods and the like.
- the present invention also provides a method for producing a monoclonal antibody or antigen-binding fragment thereof that specifically binds thioredoxin 1, comprising culturing the host cell.
- Cultivation of host cells for the production of antibodies or antigen-binding fragments thereof may be carried out according to suitable media and culture conditions known in the art.
- This culture process can be used by those skilled in the art can be easily adjusted according to the strain selected.
- Cell culture is divided into a batch culture, a fed-batch, and a continuous culture depending on the suspension culture and adhesion culture, the culture method according to the growth method of the cell.
- the medium used for culturing must adequately meet the requirements of the particular strain.
- the medium used for culturing animal cells contains various carbon sources, nitrogen sources and trace element components.
- carbon sources that can be used are glucose, sucrose, lactose, fructose, maltose, carbohydrates such as starch and cellulose, fats such as soybean oil, sunflower oil, castor oil and coconut oil, fatty acids such as palmitic acid, stearic acid and linoleic acid, Alcohols such as glycerol and ethanol, and organic acids such as acetic acid.
- carbon sources may be used alone or in combination.
- nitrogen sources examples include organic nitrogen sources and urea such as peptone, yeast extract, gravy, malt extract, corn steep liquor (CSL) and soybean wheat, inorganic urea such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate Contains nitrogen sources. These nitrogen sources may be used alone or in combination.
- the medium may include potassium dihydrogen phosphate, dipotassium hydrogen phosphate and the corresponding sodium-containing salts as a person. It may also include metal salts such as magnesium sulfate or iron sulfate.
- amino acids, vitamins, and appropriate precursors may be included.
- compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid can be added to the culture in an appropriate manner to adjust the pH of the culture.
- antifoaming agents such as fatty acid polyglycol esters can be used to suppress bubble generation.
- oxygen or oxygen-containing gas eg, air
- the temperature of the culture is usually 20 ° C to 45 ° C, preferably 25 ° C to 40 ° C.
- Antibodies obtained by culturing host cells can be used without purification and can be further purified and purified using various conventional methods such as dialysis, salt precipitation and chromatography. Among them, a method using chromatography is most used, and the type and order of columns can be selected from ion exchange chromatography, size exclusion chromatography, affinity chromatography, and the like according to the characteristics of the antibody and the culture method.
- the present invention also provides a breast cancer diagnostic kit comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention and a method for providing information necessary for diagnosing breast cancer using the same.
- diagnosis means identifying the presence or characteristic of a pathological condition.
- diagnosis is to determine whether breast cancer develops.
- Thioredoxin 1 protein is a diagnostic marker for breast cancer, and the expression level is higher in breast cancer tissues than in normal breast tissues.
- the breast cancer diagnostic kit may be an Enzyme Linked Immunosorbent Assay (ELISA) kit, preferably one selected from the group consisting of direct ELISA, indirect ELISA, direct sandwich ELISA, and indirect sandwich ELISA. It may be abnormal.
- the two antibodies included in the sandwich ELISA kit include monoclonal antibody B266-1 as a coating antibody and monoclonal antibody B264 as a detection antibody.
- the breast cancer diagnostic kits of the present invention may further comprise tools or reagents known in the art for use in immunological assays in addition to antibodies to Trx1.
- Immunological analysis in the above may include any method that can measure the binding of the antigen and the antibody.
- Such methods are known in the art and include, for example, Western blots, ELISAs, radioimmunoassays, radioimmunoassays, immunofluorescence assays, immunoblots, ocreronid immunodiffusions, rocket immunoelectrophoresis, tissue immunostaining, immunity Precipitation assay, complement fixation assay, immunochromatography assay, FACS, protein chip, and the like, but are not limited thereto.
- Tools or reagents used in immunological assays can include suitable carriers or supports, labels capable of producing detectable signals, solubilizers, detergents, stabilizers, and the like.
- Suitable carriers include, but are not limited to, substrates capable of measuring enzymatic activity, secondary antibodies labeled with suitable buffers, chromophores or fluorescent substances, chromogenic substrates, and reactions when the marker is an enzyme. And the like.
- Antibodies against Trx1, included in the kits of the present invention can preferably be immobilized to a suitable carrier or support using various methods as disclosed in the literature, and examples of suitable carriers or supports include PBS, polystyrene, polyethylene, poly Propylene, Polyester, Polyacrylonitrile, Fluorine Resin, Agarose, Cellulose, Nitrocellulose, Dextran, Sephadex, Sepharose, Liposome, Carboxymethyl Cellulose, Polyacrylamide, Polyester, Cat Rock, Filter Paper, Ion Exchange Resin , Plastic films, plastic tubes, polyamine-methyl vinyl-ether-maleic acid copolymers, amino acid copolymers, ethylene-maleic acid copolymers, nylon, metals, glass, glass beads, magnetic particles, and the like.
- Other solid substrates include cell culture plates, ELISA plates, tubes and polymeric membranes.
- the support may have any possible form, for example spherical (bead), cylindrical (test tube or inner surface of the well), planar (sheet, test strip).
- Labels capable of generating a detectable signal enable qualitative or quantitative measurement of antigen-antibody complex formation, examples of which include enzymes, fluorescent materials, ligands, luminescent materials, microparticles, redox molecules and radioactive substances. Isotopes, etc. may be used. Enzymes include ⁇ -glucuronidase, ⁇ -D-glucosidase, urease, peroxidase (such as horseradish peroxidase), alkaline phosphatase, acetylcholinesterase, glycoside oxidase, hexokinase, horses.
- enzymes include ⁇ -glucuronidase, ⁇ -D-glucosidase, urease, peroxidase (such as horseradish peroxidase), alkaline phosphatase, acetylcholinesterase, glycoside oxidase, hexokinase, horses.
- Late dihydrogenase glucose-6-phosphate dihydrogenase, invertase, luciferase and the like can be used.
- fluorescent substance fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, fluorine isothiocyanate, etc. may be used.
- Ligands include biotin derivatives, and light emitting materials include acridinium ester and luciferin.
- the microparticles include colloidal gold and colored latex, and the redox molecules include ferrocene, ruthenium complex, biologen, quinone, Ti ion, Cs ion, diimide, 1,4-benzoquinone and hydroquinone.
- Radioisotopes include 3 H, 14 C, 32 P, 35 S, 36 Cl, 51 Cr, 57 Co, 58 Co, 59 Fe, 90 Y, 125 I, 131 I, 186 Re, and the like. However, any of those that can be used in immunological assays other than those exemplified above may be used.
- HRP horseradish peroxidase
- 3-amino-9-ethylcarbazole 5-aminosalicylic acid
- 4-chloro-1-naphthol 4-chloro-1-naphthol
- o -Phenylenediamine 2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)
- 3,3-diaminobenzidine 3,3 ', 5,5'-tetramethylbenzidine, o- Dianisidine, or a solution containing 3,3-dimethoxybenzidine
- HRP horseradish peroxidase
- alkaline phosphatase when alkaline phosphatase is selected as the enzyme label, a solution containing 5-bromo-4-chloro-3-indolyl phosphate, nitroblue tetrazolium, or p-nitrophenyl phosphate can be used as the substrate.
- ⁇ -D-galactosidase when ⁇ -D-galactosidase is selected as the enzyme label, o-nitrophenyl- ⁇ -D-galactosid or 5-bromo-4-chloro-3-indole- ⁇ -D-gal is used as a substrate.
- a solution containing lactopyranoside can be used.
- various enzymes and enzyme chromogenic substrates known in the art may be used.
- the method for providing information necessary for diagnosing breast cancer of the present invention may be performed by the following steps:
- step (c) comparing the expression level of the thioredoxin 1 protein measured in step (b) with the control group and determining the breast cancer patient if the expression level of the protein is higher than that of the control group.
- the method for providing information necessary for diagnosis in the breast cancer of the present invention may be performed by the following steps:
- step (g) comparing the expression level of the thioredoxin 1 protein measured in step (f) with the control group, and determining the breast cancer patient if the expression level of the protein is higher than that of the control group.
- the term “isolated biological sample” refers to tissue (breast tissue), cells (breast cells), whole blood, plasma, serum, blood, saliva, synovial fluid, urine, which differ in the expression level of the Trx1 protein, a breast cancer marker. Sputum, lymphatic fluid, cerebrospinal fluid, tissue autopsy samples (brain, skin, lymph nodes, spinal cord, etc.), cell culture supernatants, or ruptured eukaryotic cells, and the like, and include samples from metastatic lesions as well as the primary lesion of cancer. The expression level of the Trx1 protein can be confirmed by reacting these biological samples with or without manipulation of the monoclonal antibody of the present invention.
- the term "individual” includes mammals, birds, and the like, including cattle, pigs, sheep, chickens, dogs, humans, and the like, and individuals without suspicion of breast cancer are included without limitation.
- Primer sequences used to amplify the human thioredoxin 1 gene are shown in Table 2 below.
- hTrx1 -For TAATGGTCAAACAGATCGAATC (SEQ ID NO 26)
- hTrx1 -Rev CACCAGTTCGTTAATCGTGGTAATGAAAGCT (SEQ ID NO 27)
- PCR was performed to amplify the gene for cloning into the plasmid. 10 pmol, dNTP (2.5 mM each), Exprime Taq polymerase, and buffer were added and mixed with the synthesized gene and primers (hTrx1-For, hTrx1-Rev). After 95 degreeC and this reaction for 2 minutes, 95 degreeC 30 second, 55 degreeC 30 second, and 70 degreeC 20 second reaction were repeated 35 times, and it reacted for 70 degreeC 2 minutes, and reaction was complete
- the plasmid is purified by processing the restriction enzyme to clone to the Eco R V position present in the multi-cloning site (MCS) of the pUC57 plasmid.
- MCS multi-cloning site
- the purified gene, the restriction enzyme treated plasmid, ligase and the buffer solution were mixed and reacted.
- Plasmid E. coli To transform into DH5 ⁇ , the E. coli DH5 ⁇ competent cell line was dissolved at 4 ° C., mixed with the plasmid mixed solution, and reacted at 4 ° C. for 30 minutes. After the reaction, a thermal shock was applied at 42 ° C. for 30 seconds, and then again stabilized at 4 ° C. for 2 minutes. Incubated for at least 16 hours. Plasmids with human thioredoxin 1 gene were selected from colonies grown in the culture medium.
- Trx1 Expression and Purification of Trx1
- the E. coli BL21 strain was transformed according to the above-mentioned method to express the protein.
- the cell line obtained for pure purification of this protein was disrupted by centrifugation (12,000 rpm, 30 minutes, 4 ° C.) using an ultrasonic cell crusher (sonication) to obtain a supernatant.
- Protein A / G PLUS-Agarose sc-2003, Santa Cruz
- thioredoxin I expressed by adding the purchased anti-thioredoxin I antibody (LF-MA0055, Abfrontier) to the obtained supernatant
- the reaction was carried out by addition and purified by centrifugation. Purity and quantification were then confirmed on SDS-PAGE.
- Purified human thioredoxin 1 protein was injected into mice (BALB / c) mixed with adjuvant, and blood was collected from the mice to confirm antibody production by ELISA. After two immunizations, titers of antibodies (1: 5,000) were found to increase appropriately.
- Spleens from the immunized mice were removed to isolate B lymphocytes and then fused with cultured myeloma cells (sp2 / 0).
- the fused cells were cultured in a medium (HAT medium) to which hypoxanthine, aminopterine, and thymidine were added to selectively select fusion cells of only myeloma and B lymphocytes (hybridoma). Incubated.
- HAT medium hypoxanthine, aminopterine, and thymidine
- Three antibodies that react with human thioredoxin 1 protein in the obtained hybridoma cells were identified by ELISA. Cells that are ELISA positive were selected for hybridomas that produce antibodies that respond to antigens using the limiting dilution method.
- hybridomas human immunodeficiency virus
- ascites The obtained three hybridomas (hybridoma) was injected into the mice to obtain ascites, which was purified purely using Protein A affinity chromatography. Purified antibodies were confirmed by SDS-PAGE.
- the heavy chain of monoclonal antibody 2B4 was identified as IgG1, the heavy chain of monoclonal antibody 8F3 as IgG12a, the heavy chain of monoclonal antibody 9G7 as IgG2b, and all light chains were kappa ( ⁇ ). It was confirmed that.
- the heavy and light chain amino acid sequences of 9G7 (AB1) and 2B4 (AB2) of the three monoclonal antibodies obtained in Example 2 were analyzed.
- the amino acid sequence was determined as a sequence capable of fusion with an Fc region suitable for backtranslation and recombination expression.
- the sequences determined through the IMTG gap arrangement were arranged and the hypermutation table was used to find the hypermutation and the complete CDR3 moiety.
- the sequence was confirmed by accurate mass peptide maps (accurate mass peptide maps) and the like (FIGS. 2 and 3), and MS / MS spectra were used to identify overmutations and CDR3.
- 9G7 (AB1) was selected as 4 species (B266, B297, B268 and B269), and 2B4 (AB2) was 2 species (B264). And B265) to change the base sequence to synthesize a gene.
- Trx1-Fc antigen Antibody ID 5000 ⁇ (OD Value) AB264-T150514-7 1.171 AB264-T150514-8 0.494 B265-T150514-10 0.378 B265-T150514-9 0.273 B266-T150519-3 0.198 B266-T150519-4 0.181 B267-T150519-5 0.043 B267-T150519-6 0.023 B268-T150519-8 0.015 B268-T150519-7 0.003 B269-T150519-9 0.002 B269-T150519-10 -0.001
- Trx1-His antigen Antibody ID 5000 ⁇ (OD Value) AB264-T150514-7 1.996 B265-T150514-10 1.465 AB264-T150514-8 1.142 B265-T150514-9 1.03 B267-T150519-5 0.857 B268-T150519-8 0.783 B269-T150519-9 0.77 B268-T150519-7 0.761 B269-T150519-10 0.717 B266-T150519-3 0.696 B266-T150519-4 0.667 B267-T150519-6 0.554
- amino acid sequences of the high affinity antibodies B264 and B266 are shown in Table 6 below.
- 100 ⁇ l coating buffer per well (0.015 M Na 2 CO 3 , 0.035 M NaHCO 3 , 0.003 M NaN 3 , pH9.6) and 100 ng coated antibody (coating antibody, B266) were mixed and dispensed, followed by O / N reaction at 4 ° C.
- 20 ⁇ l of the antigen 50, 25, 12.5 or 0 ng
- 80 ⁇ l of the detection antibody Biotin-labeled B264; B264-B
- the reaction was performed for 10 minutes under dark and dark conditions, and treated with 100 ⁇ l of 2.5 M sulfuric acid solution (H 2 SO 4 ; STOP buffer) per well, and the result was confirmed at 450 nm. .
- plasmids with heavy chains in the recombinant plasmids were co-infected with plasmids with other isotype heavy chains. That is, plasmids having genes encoding heavy chains other than pcDNA3-SSJ12-H among the pcDNA3-SSJ12-L and pcDNA3-SSJ12-H used for expressing 9G7 (AB1) were co-transfected.
- amino acid sequences of the light chain CDR1 to CDR3 and heavy chain CDR1 to CDR3 of the finally selected monoclonal antibodies B264 and B266-1 are shown in Table 9, and the amino acid sequences of the light chain variable region and heavy chain variable region are shown in Table 10.
- B264 light chain CDR1 SRISYM (SEQ ID NO: 1) B264 light chain CDR2 DTS (SEQ ID NO: 2) B264 light chain CDR3 HQRSSYP (SEQ ID NO: 3) B264 heavy chain CDR1 GFNIKDTF (SEQ ID NO: 4)
- B264 heavy chain CDR2 IDPANGNT (SEQ ID NO: 5) B264 heavy chain CDR3 A (SEQ ID NO: 6)
- B266-1 light chain CDR1 QSIVHSNGNTY (SEQ ID NO: 7) B266-1 light chain CDR2 KVS (SEQ ID NO: 8) B266-1 light chain CDR3 FQGSHVP (SEQ ID NO: 9)
- B266-1 heavy chain CDR1 GFNIKDTF (SEQ ID NO: 10)
- B266-1 heavy chain CDR2 IDPANGNT (SEQ ID NO: 11)
- B266-1 heavy chain CDR3 A (SEQ ID NO: 12)
- B264 light chain variable region QIVLTQSPAIMSASPGEKVTMTCSASSRISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAEDAATYYCHQRSSYP (SEQ ID NO: 13)
- B266-1 light chain variable region DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVP (SEQ ID NO: 15)
- 100 ⁇ l coating buffer per well and 100 ng coated antibody (B266-1) were mixed and dispensed, followed by O / N reaction at 4 ° C., the reaction solution was removed, and 200 ⁇ l wash buffer was dispensed and washed per well. This procedure was treated twice.
- the blank value was high due to the reaction force of B266-1, but the binding degree of B266-1 and B264 increased with increasing antigen concentration. It was confirmed. This indicates that B266-1 and B264 bind antigen.
- the K D (equilibrium dissociation constant) value B266-1 are 1.1x10 -11, B264 was 1.3x10 -10. If the K D value is between 10 -10 and 10 -12 , it is assessed as having a sensitivity to picomolar (pM) levels of antigens, indicating that B266-1 and B264 have high levels of sensitivity to antigens. have.
- Sandwich ELISA using the coated antibody (B266-1) was prepared by the following procedure.
- a coating antibody solution of 1 ⁇ g / ml concentration was prepared by adding 100 ml of coating buffer and 0.1 ml of B266-1 at 1 mg / ml concentration. 100 ⁇ l of the prepared coated antibody solution was dispensed per well of each 96-well plate, followed by reaction at 4 ° C. for 12 hours. The antibody solution was removed and washed by aliquoting 200 ⁇ l 0.05% PBST per well. This washing process was repeated three times. 200 ⁇ l PBSA was treated per well and reacted at 4 ° C. for 4 hours (blocking step). PBSA was removed and the 96-well plate was dried for 3 hours in a thermo-hygrostat (20 ° C., 30% R.H.).
- the detection antibody (B264) was biotinylated by the following procedure.
- Standard antigen solution was dispensed into the first column of 96-well plates prepared by coating with the coating antibody. Serum obtained from 20 ⁇ l breast cancer patients was dispensed, followed by 80 ⁇ l (0.3 mg / ml) B264-B solution. After reaction at 37 ° C. for 60 minutes, the antigen and antibody reaction solutions were removed, and 200 ⁇ l PBST was aliquoted and washed. This washing process was repeated three times. 100 ⁇ l of streptavidin-HRP diluted to 1: 400 was dispensed and reacted at 37 ° C. for 30 minutes. After the reaction was completed, the reaction solution was removed, and 200 ⁇ l PBST was dispensed and washed per well. This washing process was repeated three times. 100 ⁇ l TMB solution (Sure Blue) was treated and reacted at room temperature for 15 minutes under dark conditions. 100 ⁇ l of 2N H 2 SO 4 solution was aliquoted and measured at 450 nm absorbance using a microplate reader.
- Sensitivity and specificity were calculated by analyzing the results of ELISA using monoclonal antibodies B266-1 and B264 against Trx1. When the cut-off value was 10.8 ng / ml, the sensitivity was 93.0% and the specificity was 97.4% (FIG. 9).
- the monoclonal antibody of the present invention has excellent binding affinity for thioredoxin 1, which binds specifically to thioredoxin 1, and also has high sensitivity and specificity, and thus may be useful for screening breast cancer patients. Furthermore, detection of thioredoxin 1 using a monoclonal antibody that specifically binds to thioredoxin 1 of the present invention, rather than detection of another conventional breast cancer diagnostic biomarker CA15-3, has sensitivity and specificity. Its superiority can significantly increase the accuracy and reliability of breast cancer diagnosis, and thus is highly industrially applicable.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
염기서열 | |
Trx 1 유전자 | ATGGTCAAACAGATCGAATCAAAAACCGCATTTCAAGAAGCCCTGGACGCCGCTGGTGACAAACTGGTCGTGGTGGACTTTAGTGCTACCTGGTGCGGCCCGTGTAAAATGATTAAACCGTTTTTCCATAGCCTGTCTGAAAAATACAGTAACGTTATCTTTCTGGAAGTGGATGTTGATGACTGCCAGGACGTCGCGAGCGAATGCGAAGTGAAATGTATGCCGACGTTCCAGTTTTTCAAAAAAGGTCAAAAAGTCGGTGAATTTAGCGGTGCCAACAAAGAAAAACTGGAAGCCACGATTAACGAACTGGTG (서열번호 25) |
hTrx1 -For | TAATGGTCAAACAGATCGAATC (서열번호 26 ) |
hTrx1 -Rev | CACCAGTTCGTTAATCGTGGTAATGAAAGCT (서열번호 27 ) |
Antibody ID | 5000×(OD Value) |
AB264-T150514-7 | 2.0575 |
B265-T150514-10 | 1.3225 |
AB264-T150514-8 | 1.1635 |
B265-T150514-9 | 0.9515 |
B267-T150519-5 | 0.8155 |
B269-T150519-9 | 0.735 |
B268-T150519-8 | 0.716 |
B268-T150519-7 | 0.670 |
B266-T150519-3 | 0.6625 |
B266-T150519-4 | 0.6615 |
B269-T150519-10 | 0.626 |
B267-T150519-6 | 0.522 |
Antibody ID | 5000×(OD Value) |
AB264-T150514-7 | 1.171 |
AB264-T150514-8 | 0.494 |
B265-T150514-10 | 0.378 |
B265-T150514-9 | 0.273 |
B266-T150519-3 | 0.198 |
B266-T150519-4 | 0.181 |
B267-T150519-5 | 0.043 |
B267-T150519-6 | 0.023 |
B268-T150519-8 | 0.015 |
B268-T150519-7 | 0.003 |
B269-T150519-9 | 0.002 |
B269-T150519-10 | -0.001 |
Antibody ID | 5000×(OD Value) |
AB264-T150514-7 | 1.996 |
B265-T150514-10 | 1.465 |
AB264-T150514-8 | 1.142 |
B265-T150514-9 | 1.03 |
B267-T150519-5 | 0.857 |
B268-T150519-8 | 0.783 |
B269-T150519-9 | 0.77 |
B268-T150519-7 | 0.761 |
B269-T150519-10 | 0.717 |
B266-T150519-3 | 0.696 |
B266-T150519-4 | 0.667 |
B267-T150519-6 | 0.554 |
아미노산 서열 | |
B264 경쇄 | QIVLTQSPAIMSASPGEKVTMTCSASSRISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAEDAATYYCHQRSSYPTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (서열번호 17) |
B264 중쇄 | EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCALLQYSAMDYWGQGTSVTVSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPG (서열번호 18) |
B266 경쇄 | DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (서열번호 19) |
B266 중쇄 | QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPTSDYTNYNQKFKDKATLTADKSSSTAYMQLSSLTSEDSAVYFCASEGGFLYYFDYWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (서열번호 20) |
유전자 서열 | |
B264 경쇄 | GACGTGCTGATGACACAGACACCACTCAGCCTCCCTGTGAGCCTGGGCGACCAGGCCTCTATTTCTTGCCGGTCTAGCCAGAGCATCGTGCACTCCAACGGCAACACATACTTGGAGTGGTATCTACAGAAGCCCGGCCAGTCCCCTAAGCTGCTGATATACAAGGTGTCTAACCGCTTCTCCGGCGTGCCCGACAGGTTCTCTGGCAGCGGCTCTGGCACCGACTTCACCCTCAAAATATCTAGGGTGGAGGCCGAGGACCTGGGCGTGTACTACTGCTTCCAGGGCTCCCACGTTCCATACACATTCGGCGGCGGCACAAAGTTGGAAATTAAGCGCGCTGACGCAGCCCCAACAGTGAGCATCTTTCCTCCATCCTCTGAACAACTTACCTCTGGAGGAGCCTCTGTGGTGTGTTTCCTGAACAACTTCTACCCAAAGGACATCAATGTGAAGTGGAAGATTGATGGCTCTGAGAGACAGAATGGAGTGCTGAACTCCTGGACAGACCAGGACAGCAAGGACAGCACCTACAGTATGAGTAGCACCCTGACCCTGACCAAGGATGAATATGAGAGACACAACTCCTACACTTGTGAGGCTACCCACAAGACCAGCACCAGCCCAATTGTCAAATCCTTCAACAGGAATGAGTGTTAA (서열번호 21) |
B264 중쇄 | CTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCCCATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTGCACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAATAA (서열번호 22) |
B266 경쇄 | CAGATCGTGCTCACACAGTCTCCAGCCATCATGAGCGCCTCTCCTGGCGAGAAGGTGACAATGACCTGCTCTGCCTCTAGCCGCATTTCTTACATGTACTGGTATCAGCAGAAGCCAGGCACCTCCCCTAAGAGGTGGATATACGACACATCCAAGCTGGCCTCCGGCGTGCCCGCCCGGTTCAGCGGCTCTGGCAGCGGCACAAGCTACTCCCTGACAATTAGCACGATGGAGGCCGAGGACGCCGCCACATACTACTGCCACCAGCGCTCGTCCTACCCAACATTCGGCGCCGGCACAAAATTGGAACTGAAGAGAGCTGACGCAGCCCCAACAGTGAGCATCTTTCCTCCATCCTCTGAACAACTTACCTCTGGAGGAGCCTCTGTGGTGTGTTTCCTGAACAACTTCTACCCAAAGGACATCAATGTGAAGTGGAAGATTGATGGCTCTGAGAGACAGAATGGAGTGCTGAACTCCTGGACAGACCAGGACAGCAAGGACAGCACCTACAGTATGAGTAGCACCCTGACCCTGACCAAGGATGAATATGAGAGACACAACTCCTACACTTGTGAGGCTACCCACAAGACCAGCACCAGCCCAATTGTCAAATCCTTCAACAGGAATGAGTGTTAA (서열번호 23) |
B266 중쇄 | CAATTTCTAAGATTAAGGGCCTGGTGCGCGCCCCTCAGGTGTACATTCTGCCTCCTCCCGCCGAGCAGCTGAGCCGGAAGGACGTGTCCCTCACATGCCTCGTGGTGGGCTTCAACCCTGGCGACATTAGCGTGGAGTGGACATCTAACGGCCACACAGAAGAAAACTACAAGGACACAGCCCCTGTGCTCGACTCCGACGGCTCTTACTTCATATACTCTAAGCTGAACATGAAAACATCTAAGTGGGAAAAGACCGACTCTTTCTCTTGCAACGTGCGGCACGAGGGCCTGAAGAACTACTACCTCAAGAAAACCATTAGCAGAAGTCCAGGCTAA (서열번호 24) |
Trx1 (ng/㎖) | 0 | 12.5 | 25 | 50 |
O.D.450nm | 0.828 | 1.226 | 1.506 | 2.257 |
아미노산 서열 | |
B264 경쇄 CDR1 | SRISYM (서열번호 1) |
B264 경쇄 CDR2 | DTS (서열번호 2) |
B264 경쇄 CDR3 | HQRSSYP (서열번호 3) |
B264 중쇄 CDR1 | GFNIKDTF (서열번호 4) |
B264 중쇄 CDR2 | IDPANGNT (서열번호 5) |
B264 중쇄 CDR3 | A (서열번호 6) |
B266-1 경쇄 CDR1 | QSIVHSNGNTY (서열번호 7) |
B266-1 경쇄 CDR2 | KVS (서열번호 8) |
B266-1 경쇄 CDR3 | FQGSHVP (서열번호 9) |
B266-1 중쇄 CDR1 | GFNIKDTF (서열번호 10) |
B266-1 중쇄 CDR2 | IDPANGNT (서열번호 11) |
B266-1 중쇄 CDR3 | A (서열번호 12) |
아미노산 서열 | |
B264 경쇄 가변영역 | QIVLTQSPAIMSASPGEKVTMTCSASSRISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAEDAATYYCHQRSSYP (서열번호 13) |
B264 중쇄 가변영역 | EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSED TAVYYCA (서열번호:14) |
B266-1 경쇄 가변영역 | DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVP (서열번호:15) |
B266-1중쇄 가변영역 | EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCA (서열번호:16) |
Trx1 (ng/㎖) | 0 | 25 | ||
O.D.450nm | 0.425 | 0.415 | 1.571 | 1.426 |
Trx1 | CA15-3 (AxSYM) | |
Sensitivity(%) | 93 | 54 |
Specificity(%) | 97.4 | 94 |
Test sample | Serum | Serum과 plasma |
Claims (31)
- 서열번호 1의 아미노산 서열로 이루어진 경쇄 CDR1, 서열번호 2의 아미노산 서열로 이루어진 경쇄 CDR2 및 서열번호 3의 아미노산 서열로 이루어진 경쇄 CDR3을 포함하는 경쇄 가변영역, 및 서열번호 4의 아미노산 서열로 이루어진 중쇄 CDR1, 서열번호 5의 아미노산 서열로 이루어진 중쇄 CDR2 및 서열번호 6의 아미노산 서열로 이루어진 중쇄 CDR3을 포함하는 중쇄 가변영역을 포함하는, 티오레독신 1에 특이적으로 결합하는 단일클론항체 또는 이의 항원 결합 단편.
- 서열번호 7의 아미노산 서열로 이루어진 경쇄 CDR1, 서열번호 8의 아미노산 서열로 이루어진 경쇄 CDR2 및 서열번호 9의 아미노산 서열로 이루어진 경쇄 CDR3을 포함하는 경쇄 가변영역, 및 서열번호 10의 아미노산 서열로 이루어진 중쇄 CDR1, 서열번호 11의 아미노산 서열로 이루어진 중쇄 CDR2 및 서열번호 12의 아미노산 서열로 이루어진 중쇄 CDR3을 포함하는 중쇄 가변영역을 포함하는, 티오레독신 1에 특이적으로 결합하는 단일클론항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 상기 항체는 서열번호 13의 아미노산 서열로 이루어진 경쇄 가변영역 및 서열번호 14의 아미노산 서열로 이루어진 중쇄 가변영역을 포함하는 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제2항에 있어서, 상기 항체는 서열번호 15의 아미노산 서열로 이루어진 경쇄 가변영역 및 서열번호 16의 아미노산 서열로 이루어진 중쇄 가변영역을 포함하는 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 상기 항체는 서열번호 17의 아미노산 서열로 이루어진 경쇄 및 서열번호 18의 아미노산 서열로 이루어진 중쇄를 포함하는 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제2항에 있어서, 상기 항체는 서열번호 19의 아미노산 서열로 이루어진 경쇄 및 서열번호 20의 아미노산 서열로 이루어진 중쇄를 포함하는 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 항체는 IgG1 중쇄 및 카파(κ) 경쇄를 포함하는 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 항원 결합 단편은 Fab, F (ab'), F (ab')2, Fv 또는 단쇄 항체 분자인 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 항체는 키메라 항체, 인간화 항체 또는 인간 항체인 것을 특징으로 하는 단일클론항체 또는 이의 항원 결합 단편.
- 제1항의 단일클론항체 또는 이의 항원 결합 단편의 경쇄를 코딩하는 핵산분자.
- 제10항에 있어서, 상기 핵산분자는 서열번호 21의 뉴클레오티드 서열로 이루어진 것을 특징으로 하는 핵산분자.
- 제1항의 단일클론항체 또는 이의 항원 결합 단편의 중쇄를 코딩하는 핵산분자.
- 제12항에 있어서, 상기 핵산분자는 서열번호 22의 뉴클레오티드 서열로 이루어진 것을 특징으로 하는 핵산분자.
- 제2항의 단일클론항체 또는 이의 항원 결합 단편의 경쇄를 코딩하는 핵산분자.
- 제14항에 있어서, 상기 핵산분자는 서열번호 23의 뉴클레오티드 서열로 이루어진 것을 특징으로 하는 핵산분자.
- 제2항의 단일클론항체 또는 이의 항원 결합 단편의 중쇄를 코딩하는 핵산분자.
- 제16항에 있어서, 상기 핵산분자는 서열번호 24의 뉴클레오티드 서열로 이루어진 것을 특징으로 하는 핵산분자.
- 제10항의 경쇄를 코딩하는 핵산분자, 제12항의 중쇄를 코딩하는 핵산분자 또는 상기 핵산분자 모두를 포함하는 재조합 벡터.
- 제14항의 경쇄를 코딩하는 핵산분자, 제16항의 중쇄를 코딩하는 핵산분자 또는 상기 핵산분자 모두를 포함하는 재조합 벡터.
- 제18항의 재조합 벡터를 포함하는 숙주세포.
- 제19항의 재조합 벡터를 포함하는 숙주세포.
- 제20항 또는 제21항의 숙주세포를 배양하는 단계를 포함하는, 티오레독신 1에 특이적으로 결합하는 단일클론항체 또는 이의 항원 결합 단편의 제조방법.
- 제1항 내지 제6항 중 어느 한 항의 단일클론항체 또는 이의 항원 결합 단편을 포함하는 유방암 진단 키트.
- 제23항에 있어서, 상기 키트는 ELISA(Enzyme Linked Immunosorbent Assay) 키트인 것을 특징으로 하는 유방암 진단 키트.
- 제24항에 있어서, 상기 ELISA는 직접 ELISA, 간접 ELISA, 직접적 샌드위치 ELISA 및 간접적 샌드위치 ELISA로 이루어진 군에서 선택된 1종 이상인 것을 특징으로 하는 유방암 진단 키트.
- (a) 제1항 내지 제6항 중 어느 한 항의 단일클론항체 또는 이의 항원 결합 단편을 유방암이 의심되는 개체로부터 분리된 생물학적 시료에 접촉시키는 단계;(b) 항원-항체 복합체 형성을 통해 상기 생물학적 시료에서 단일클론항체 또는 이의 항원 결합 단편에 결합된 티오레독신 1 단백질의 발현 수준을 측정하는 단계; 및(c) 상기 (b) 단계에서 측정된 티오레독신 1 단백질의 발현 수준을 대조군과 비교하여 대조군에 비해 상기 단백질의 발현 수준이 높으면 유방암 환자로 판정하는 단계;를 포함하는 유방암 진단에 필요한 정보를 제공하는 방법.
- 제26항에 있어서, 상기 티오레독신 1 단백질의 발현 수준은 웨스턴 블랏, ELISA, 샌드위치 ELISA, 방사선면역분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 면역침전 분석법, 보체 고정 분석법, 면역크로마토그래피 분석법, FACS 및 단백질 칩 방법 중 어느 하나 이상의 방법으로 이루어진 군에서 선택된 어느 하나의 방법으로 측정하는 것을 특징으로 하는 유방암 진단에 필요한 정보를 제공하는 방법.
- 제26항에 있어서, 상기 분리된 생물학적 시료는 전혈, 혈청, 혈장, 유방 조직 및 유방 세포로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 하는 유방암 진단에 필요한 정보를 제공하는 방법.
- (a) 고체 지지체를 제2항, 제4항 또는 제6항의 단일클론항체 또는 이의 항원 결합 단편으로 코팅하는 단계;(b) 유방암이 의심되는 개체로부터 분리된 생물학적 시료를 상기 코팅된 고체 지지체에 적용하는 단계;(c) 결합되지 않은 샘플을 제거하는 단계;(d) 제1항, 제3항 또는 제5항의 단일클론항체 또는 이의 항원 결합 단편을 고체 지지체에 적용하는 단계;(e) 결합되지 않은 단일클론항체 또는 이의 항원 결합 단편을 제거하는 단계;(f) 티오레독신 1 단백질의 발현 수준을 측정하는 단계; 및(g) 상기 (f) 단계에서 측정된 티오레독신 1 단백질의 발현 수준을 대조군과 비교하여, 대조군에 비해 상기 단백질의 발현 수준이 높으면 유방암 환자로 판정하는 단계;를 포함하는 유방암 진단에 필요한 정보를 제공하는 방법.
- 제29항에 있어서, 상기 티오레독신 1 단백질의 발현 수준은 웨스턴 블랏, ELISA, 샌드위치 ELISA, 방사선면역분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 면역침전 분석법, 보체 고정 분석법, 면역크로마토그래피 분석법, FACS 및 단백질 칩 방법 중 어느 하나 이상의 방법으로 이루어진 군에서 선택된 어느 하나의 방법으로 측정하는 것을 특징으로 하는 유방암 진단에 필요한 정보를 제공하는 방법.
- 제29항에 있어서, 상기 분리된 생물학적 시료는 전혈, 혈청, 혈장, 유방 조직 및 유방 세포로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 하는 유방암 진단에 필요한 정보를 제공하는 방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/332,623 US11002739B2 (en) | 2016-09-13 | 2016-09-13 | Monoclonal antibody specifically binding to thioredoxin 1, and use thereof |
CN201680089262.7A CN109863176B (zh) | 2016-09-13 | 2016-09-13 | 与硫氧还蛋白1特异性结合的单克隆抗体及其用途 |
EP16916308.6A EP3527589A4 (en) | 2016-09-13 | 2016-09-13 | MONOCLONAL ANTIBODIES BINDING SPECIFICALLY TO THIOREDOXIN 1 AND ITS USE |
BR112019004901A BR112019004901A2 (pt) | 2016-09-13 | 2016-09-13 | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, seu método de preparação, molécula de ácido nucleico, vetor recombinante, célula hospedeira, kit de diagnóstico e método para fornecer informações |
AU2016422911A AU2016422911B2 (en) | 2016-09-13 | 2016-09-13 | Monoclonal antibody specifically binding to thioredoxin 1, and use thereof |
JP2019515262A JP6862542B2 (ja) | 2016-09-13 | 2016-09-13 | チオレドキシン1に特異的に結合する単一クローン抗体およびその用途 |
RU2019110953A RU2747929C2 (ru) | 2016-09-13 | 2016-09-13 | Моноклональное антитело, специфически связывающееся с тиоредоксином-1, и его применение |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0118053 | 2016-09-13 | ||
KR1020160118053A KR101982782B1 (ko) | 2016-09-13 | 2016-09-13 | 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018052153A1 true WO2018052153A1 (ko) | 2018-03-22 |
Family
ID=61619658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/010381 WO2018052153A1 (ko) | 2016-09-13 | 2016-09-13 | 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11002739B2 (ko) |
EP (1) | EP3527589A4 (ko) |
JP (1) | JP6862542B2 (ko) |
KR (1) | KR101982782B1 (ko) |
CN (1) | CN109863176B (ko) |
AU (1) | AU2016422911B2 (ko) |
BR (1) | BR112019004901A2 (ko) |
RU (1) | RU2747929C2 (ko) |
WO (1) | WO2018052153A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018349387B2 (en) * | 2017-10-12 | 2022-05-19 | E&S Healthcare Co., Ltd. | Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220127679A1 (en) * | 2019-02-13 | 2022-04-28 | Bertis Inc | Composition for cancer diagnosis |
JPWO2021201202A1 (ko) * | 2020-04-02 | 2021-10-07 | ||
CN113999819B (zh) * | 2021-11-10 | 2023-11-28 | 青岛硕景生物科技有限公司 | 分泌抗Trx蛋白单克隆抗体的杂交瘤细胞株、抗Trx蛋白单克隆抗体 |
CN117487008B (zh) * | 2023-09-26 | 2024-05-28 | 武汉爱博泰克生物科技有限公司 | 抗人Lin28A蛋白的兔单克隆抗体及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06261783A (ja) * | 1993-03-16 | 1994-09-20 | Toyota Central Res & Dev Lab Inc | チオレドキシンに特異的に反応するモノクローナル抗体 |
WO2005117930A2 (en) * | 2004-06-04 | 2005-12-15 | Sloan-Kettering Institute For Cancer Research | Use of thioredoxin measurements for diagnostics and treatments |
CN101493464A (zh) * | 2009-03-09 | 2009-07-29 | 昆明理工大学 | 诊断乳腺癌的分子标记物 |
WO2010107158A1 (ko) * | 2009-03-16 | 2010-09-23 | 배재대학교 산학협력단 | 티오레독신 1을 유효성분으로 하는 유방암 진단용 마커, 및 이를 이용한 유방암 진단 키트 |
KR20160118053A (ko) | 2015-04-01 | 2016-10-11 | (주)넥스티지 | 테이프 부착 시스템 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2336168A1 (en) * | 1997-04-15 | 2011-06-22 | Sankyo Company Limited | Novel protein and method for producing the protein |
US6531648B1 (en) * | 1998-12-17 | 2003-03-11 | Syngenta Participations Ag | Grain processing method and transgenic plants useful therein |
JP4516456B2 (ja) * | 2005-03-15 | 2010-08-04 | オリンパスイメージング株式会社 | 撮像装置 |
US20110039277A1 (en) * | 2008-04-18 | 2011-02-17 | Pier Mastroberardino | Methods of Labeling Proteins |
CZ2008606A3 (cs) * | 2008-10-09 | 2010-04-21 | Ústav molekulární genetiky, v.v.i. Akademie ved Ceské republiky | Rekombinantní protein upravený pro prímou radiojodaci a jeho výroba a použití |
US9382587B2 (en) * | 2009-03-16 | 2016-07-05 | Paichai University Industry-Academic Cooperation Foundation | Diagnosis of breast cancer based on expression level of thioredoxin-1 |
US20130157292A1 (en) * | 2011-12-14 | 2013-06-20 | Paichai University Industry-Academic Cooperation Foundation | Composition for the diagnosis of ovarian cancer or pneumonia comprising thioredoxin 1 as active ingredient and use thereof |
-
2016
- 2016-09-13 WO PCT/KR2016/010381 patent/WO2018052153A1/ko unknown
- 2016-09-13 RU RU2019110953A patent/RU2747929C2/ru active
- 2016-09-13 AU AU2016422911A patent/AU2016422911B2/en active Active
- 2016-09-13 KR KR1020160118053A patent/KR101982782B1/ko active IP Right Grant
- 2016-09-13 CN CN201680089262.7A patent/CN109863176B/zh active Active
- 2016-09-13 JP JP2019515262A patent/JP6862542B2/ja active Active
- 2016-09-13 BR BR112019004901A patent/BR112019004901A2/pt active Search and Examination
- 2016-09-13 US US16/332,623 patent/US11002739B2/en active Active
- 2016-09-13 EP EP16916308.6A patent/EP3527589A4/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06261783A (ja) * | 1993-03-16 | 1994-09-20 | Toyota Central Res & Dev Lab Inc | チオレドキシンに特異的に反応するモノクローナル抗体 |
WO2005117930A2 (en) * | 2004-06-04 | 2005-12-15 | Sloan-Kettering Institute For Cancer Research | Use of thioredoxin measurements for diagnostics and treatments |
CN101493464A (zh) * | 2009-03-09 | 2009-07-29 | 昆明理工大学 | 诊断乳腺癌的分子标记物 |
WO2010107158A1 (ko) * | 2009-03-16 | 2010-09-23 | 배재대학교 산학협력단 | 티오레독신 1을 유효성분으로 하는 유방암 진단용 마커, 및 이를 이용한 유방암 진단 키트 |
KR101058230B1 (ko) | 2009-03-16 | 2011-08-22 | 배재대학교 산학협력단 | 티오레독신 1을 유효성분으로 하는 유방암 진단용 마커, 및이를 이용한 유방암 진단 키트 |
KR20160118053A (ko) | 2015-04-01 | 2016-10-11 | (주)넥스티지 | 테이프 부착 시스템 |
Non-Patent Citations (3)
Title |
---|
DATABASE Protein 28 February 2003 (2003-02-28), "immunoglobulin light chain kappa [Mus musculus]", XP055586280, retrieved from NCBI Database accession no. CAD68984.1 * |
PARK ET AL.: "Thioredoxin 1 as a Serum Marker for Breast Cancer and Its Use in Combination with CEA or CA 15-3 for Improving the Sensitivity of Breast Cancer Diagnoses", BMC RESEARCH NOTES, vol. 7, no. 7, 6 January 2014 (2014-01-06), pages 1 - 12, XP021173712 * |
See also references of EP3527589A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018349387B2 (en) * | 2017-10-12 | 2022-05-19 | E&S Healthcare Co., Ltd. | Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto |
US11953502B2 (en) | 2017-10-12 | 2024-04-09 | E&S Healthcare Co., Ltd. | Thioredoxin 1 epitope, encoding nucleic acid and methods of binding a monoclonal antibody |
Also Published As
Publication number | Publication date |
---|---|
JP2019532630A (ja) | 2019-11-14 |
EP3527589A1 (en) | 2019-08-21 |
KR20180029673A (ko) | 2018-03-21 |
CN109863176A (zh) | 2019-06-07 |
CN109863176B (zh) | 2023-04-21 |
AU2016422911A1 (en) | 2019-04-04 |
RU2747929C2 (ru) | 2021-05-17 |
EP3527589A4 (en) | 2020-08-26 |
KR101982782B1 (ko) | 2019-05-28 |
RU2019110953A3 (ko) | 2020-10-15 |
AU2016422911B2 (en) | 2021-04-01 |
BR112019004901A2 (pt) | 2019-06-25 |
US11002739B2 (en) | 2021-05-11 |
US20200200750A1 (en) | 2020-06-25 |
JP6862542B2 (ja) | 2021-04-21 |
RU2019110953A (ru) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019074333A9 (ko) | 티오레독신 1 에피토프 및 이에 특이적으로 결합하는 단일클론항체 | |
WO2018052153A1 (ko) | 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도 | |
CN110167967B (zh) | 针对抗pd-l1抗体的独特型抗体及其用途 | |
WO2020036403A1 (ko) | 메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도 | |
WO2017010744A1 (ko) | 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법 | |
WO2017116212A1 (ko) | 마이코박테리아 유래 항원에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 | |
WO2023038477A1 (ko) | 코로나바이러스 뉴클레오캡시드 단백질에 특이적인 항체 및 이의 용도 | |
WO2022154288A1 (ko) | 단백질 키나아제 a의 촉매 서브 유닛 알파에 특이적으로 결합하는 단일클론항체 및 이를 활용한 암 진단 용도 | |
WO2022231321A1 (ko) | Sars-cov-2 rbd 항원 특이적 항체를 포함하는 진단용 조성물 또는 키트 | |
WO2017179862A1 (ko) | 안정성이 개선된 her2에 특이적으로 결합하는 항체 | |
WO2021112640A1 (ko) | 항-tm4sf4 항체 및 이의 용도 | |
WO2020159229A1 (ko) | Ccsp-2에 특이적으로 결합하는 단일클론항체 및 이의 용도 | |
WO2018182266A1 (ko) | 항-emap ii 항체 및 이의 용도 | |
WO2021137655A1 (ko) | SUPER-REPRESSOR IκB에 대한 항체 및 이의 용도 | |
KR102269281B1 (ko) | 개 인플루엔자 바이러스에 특이적인 단일클론항체 및 이의 용도 | |
RU2797266C2 (ru) | Эпитоп тиоредоксина-1 и моноклональное антитело, специфически связывающееся с ним | |
KR102298278B1 (ko) | 돼지 인플루엔자 바이러스에 특이적인 단일클론항체 및 이의 용도 | |
WO2022092644A1 (ko) | Wars 중화항체 및 이의 용도 | |
RU2791264C2 (ru) | Моноклональное антитело, специфично связывающееся с эпитопом тиоредоксина-1, его получение и применение | |
WO2021107725A1 (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 | |
WO2022265439A1 (ko) | 항-tm4sf4 인간화 항체 및 이의 용도 | |
CN116802212A (zh) | 胃泌酸调节素结合分子及其用途 | |
JP2019210211A (ja) | ウシプロカルシトニンを特異的に認識する抗体、その抗原結合断片、および、その使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16916308 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019515262 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019004901 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2016422911 Country of ref document: AU Date of ref document: 20160913 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016916308 Country of ref document: EP Effective date: 20190415 |
|
ENP | Entry into the national phase |
Ref document number: 112019004901 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190313 |